胰腺癌的个性化医疗：利用信使核糖核酸疫苗的潜力
Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines.
作者信息
Hussain Aariz, Fareed Areeba
机构信息
Karachi Medical and Dental College, Pakistan.
出版信息
J Genet Eng Biotechnol. 2025 Mar;23(1):100469. doi: 10.1016/j.jgeb.2025.100469. Epub 2025 Feb 17.
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC's dense and immunosuppressive tumor environment. Emerging mRNA vaccines, such as autogene cevumeran (BNT122), show promise in enhancing treatment. Preliminary trials have reported prolonged survival with minimal side effects. Despite this progress, the complexity of PDAC remains a significant challenge. Continued research is essential to fully realize the potential of mRNA-based therapies in combating this deadly cancer.
胰腺导管腺癌（PDAC）是一种高度致命的癌症，五年生存率仅为7%。其诊断较晚且治疗选择有限，导致预后不良。由于PDAC致密且具有免疫抑制性的肿瘤微环境，免疫疗法成效甚微。新兴的mRNA疫苗，如自体基因cevideran（BNT122），在增强治疗效果方面显示出前景。初步试验报告显示患者生存期延长且副作用最小。尽管取得了这一进展，但PDAC的复杂性仍然是一个重大挑战。持续的研究对于充分发挥基于mRNA的疗法在对抗这种致命癌症方面的潜力至关重要。
Zotero 插件